Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 265

Similar articles for PubMed (Select 16406391)

2.

PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator.

Engeler DS, Schwab C, Thöni AF, Hochreiter W, Prikler L, Suter S, Stucki P, Schiefer J, Plasswilm L, Schmid HP, Putora PM.

Strahlenther Onkol. 2015 Jun 23. [Epub ahead of print]

PMID:
26100965
3.

The Importance of Prostate-specific Antigen (PSA) Nadir and Early Identification of PSA Relapse after 10 Years of Prostate Iodine125 Seed Brachytherapy in Edinburgh.

McLaren DB, Kerr G, Law AB, Brush JP, Keanie J, Malik J, Keough W, Ronaldson T, Lee J, Kehoe T.

Clin Oncol (R Coll Radiol). 2015 Jun 17. pii: S0936-6555(15)00202-2. doi: 10.1016/j.clon.2015.05.003. [Epub ahead of print]

PMID:
26093507
4.

ASTRO issues new guidance for radiotherapy in NSCLC.

Yaqub F.

Lancet Oncol. 2015 Jun;16(6):e268. doi: 10.1016/S1470-2045(15)70239-1. Epub 2015 May 11. No abstract available.

PMID:
25975634
5.

(P121) Image-Guided Radiation Therapy Utilization and Practice Patterns: Results From a National Survey of ASTRO Membership.

[No authors listed]

Oncology (Williston Park). 2015 Apr 21;29(4 Suppl 1). pii: 205136. No abstract available.

6.

Kinetics differences between PSA bounce and biochemical failure in patients treated with 125I prostate brachytherapy.

Kanzaki H, Kataoka M, Nishikawa A, Uwatsu K, Nagasaki K, Nishijima N, Hashine K.

Jpn J Clin Oncol. 2015 Jul;45(7):688-94. doi: 10.1093/jjco/hyv050. Epub 2015 Apr 17.

PMID:
25888709
7.

Professor Bruce D. Minsky: Advances in radiation oncology in 2014 ASTRO.

He MC.

Chin Clin Oncol. 2014 Dec;3(4):50. doi: 10.3978/j.issn.2304-3865.2014.10.01. No abstract available.

8.

Astro-logics with microRNAs.

Eitan C, Hornstein E.

EMBO J. 2015 May 5;34(9):1143-4. doi: 10.15252/embj.201591241. Epub 2015 Mar 3. No abstract available.

PMID:
25736376
9.

Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?

Morris LM, Izard MA, Wan WY.

Brachytherapy. 2015 May-Jun;14(3):322-8. doi: 10.1016/j.brachy.2014.11.002. Epub 2014 Dec 5.

PMID:
25487524
10.

Long-term outcome of high-risk prostate cancer treated with brachytherapy combined with external-beam radiation therapy and androgen deprivation therapy.

Chen J, Yan WG, Li HZ, Ji ZG, Zhou Y, Zhou ZE, Mai ZP.

Tumori. 2014 Sep-Oct;100(5):524-8. doi: 10.1700/1660.18170.

PMID:
25343547
11.

Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy.

Hackett C, Ghosh S, Sloboda R, Martell K, Lan L, Pervez N, Pedersen J, Yee D, Murtha A, Amanie J, Usmani N.

J Contemp Brachytherapy. 2014 Oct;6(3):247-53. doi: 10.5114/jcb.2014.45093. Epub 2014 Sep 5.

12.

Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer.

Naghavi AO, Strom TJ, Nethers K, Cruz AA, Figura NB, Shrinath K, Yue B, Kim J, Biagioli MC, Fernandez DC, Heysek RV, Wilder RB.

Int J Clin Oncol. 2015 Jun;20(3):598-604. doi: 10.1007/s10147-014-0745-8. Epub 2014 Sep 6.

PMID:
25193155
13.

Androgen deprivation therapy in prostate cancer: looking beyond prostate-specific antigen and testosterone levels.

Saad F.

Eur Urol. 2015 May;67(5):837-8. doi: 10.1016/j.eururo.2014.08.033. Epub 2014 Aug 26. No abstract available.

PMID:
25168615
14.

Patterns of failure after iodine-125 seed implantation for prostate cancer.

Lamb DS, Greig L, Russell GL, Nacey JN, Broome K, Studd R, Delahunt B, Iupati D, Jain M, Rooney C, Murray J, Lamb PJ, Bethwaite PB.

Radiother Oncol. 2014 Jul;112(1):68-71. doi: 10.1016/j.radonc.2014.07.006. Epub 2014 Jul 28.

PMID:
25082097
15.

Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy.

Patel N, Souhami L, Mansure JJ, Duclos M, Aprikian A, Faria S, David M, Cury FL.

Brachytherapy. 2014 Sep-Oct;13(5):450-5. doi: 10.1016/j.brachy.2014.05.005. Epub 2014 Jul 10.

PMID:
25023396
16.

PSA flare after initiation of abiraterone acetate.

Narmala SK, Boulmay BC.

J Community Support Oncol. 2014 May;12(5):191-2.

PMID:
24971430
17.

Commentary: Safety considerations in contemporary radiation oncology: Introduction to a series of ASTRO safety white papers.

Fraass BA, Marks LB, Pawlicki T; ASTRO Multidisciplinary Quality Assurance Subcommittee.

Pract Radiat Oncol. 2011 Jul-Sep;1(3):188-9. doi: 10.1016/j.prro.2011.04.009. Epub 2011 Jul 8. No abstract available.

PMID:
24673949
18.

A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics.

Suzuki Y, Sakai D, Nomura T, Hirata Y, Aihara K.

J Theor Biol. 2014 Jun 7;350:1-16. doi: 10.1016/j.jtbi.2014.02.004. Epub 2014 Feb 10.

PMID:
24524858
19.

Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.

Vu CC, Haas JA, Katz AE, Witten MR.

Front Oncol. 2014 Jan 28;4:8. doi: 10.3389/fonc.2014.00008. eCollection 2014.

20.

Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis.

Bernstein MB, Ohri N, Hodge JW, Garg M, Bodner W, Kalnicki S, Dicker AP, Guha C.

J Contemp Brachytherapy. 2013 Dec;5(4):210-4. doi: 10.5114/jcb.2013.38875. Epub 2013 Nov 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk